Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients.
about
Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's DiseaseParkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease PatientsAn Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with DementiaTargeted discovery and validation of plasma biomarkers of Parkinson's disease.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.Blood-based biomarkers for Parkinson's diseaseUnbiased approaches to biomarker discovery in neurodegenerative diseasesPrevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromesPlasma epidermal growth factor decreased in the early stage of Parkinson's disease.Converging mediators from immune and trophic pathways to identify Parkinson disease dementia.Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's diseaseNeurological update: dementia.What can biomarkers tell us about cognition in Parkinson's disease?Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease.Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease.Multifactorial Analysis of a Biomarker Pool for Alzheimer Disease Risk in a North Indian Population.Parkinson's Disease Biomarkers: Where Are We and Where Do We Go Next?
P2860
Q26746174-FE41FA97-EA2C-4FE3-BDDC-30E2846FB4B7Q27686837-CAB45E68-6BD6-45E3-AF47-51936198433DQ28550937-63A095EF-2E9D-4BF2-B9E5-ECB3B4E10862Q28552902-5CE5A8B9-028F-45FF-8AC1-701C68FCF50CQ30597182-C7506FF7-1EA6-4859-8A55-D291270A8DA4Q31097119-54DFB32F-1A8A-474E-97AE-8BAEEAE4D650Q33804255-5A2CD381-C586-4293-886F-C50E9A3545B2Q34625918-EEB8DF3E-60EA-47CB-8306-446B42065FD7Q35096897-8DCDB6EE-F2D5-40D2-B874-E2DB5E52CF82Q35636853-A67F42DC-1901-4BF0-A1F7-8309CDA33B01Q36521242-4C02699A-538E-4C4B-B827-1955722F9CF6Q36891717-777B0C32-23DE-4493-BADD-816DBAF90709Q38185573-D63018CC-C347-4EC4-865B-C0CD745B8CE8Q38206497-57131FE6-714B-451B-A681-7E3A3C1C3A05Q41215282-D85298E1-871E-45C5-A5FC-B447FB8FB2D9Q47338262-8FDA917E-59FD-4914-BDE4-F830669EC1B7Q50750381-6308900E-8098-48F3-B58D-7A9184F75311Q52600144-B17CE108-3512-4032-AC03-8E75757FCF96Q58585963-87DC628E-F834-4346-BDF1-4573F51BFA07
P2860
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Serum epidermal growth factor ...... Parkinson's disease patients.
@en
type
label
Serum epidermal growth factor ...... Parkinson's disease patients.
@en
prefLabel
Serum epidermal growth factor ...... Parkinson's disease patients.
@en
P2093
P2860
P50
P1433
P1476
Serum epidermal growth factor ...... Parkinson's disease patients.
@en
P2093
Anna De Rosa
Claudia Pivonello
Giuseppe De Michele
Katia Longo
Lucio Santoro
Marcello Moccia
Roberto Erro
P2860
P2888
P304
P356
10.1007/S00415-012-6648-6
P50
P577
2012-08-22T00:00:00Z
P5875
P6179
1017081040